New hope for hard-to-treat pancreatic cancer?
NCT ID NCT06981806
First seen Oct 31, 2025 · Last updated May 03, 2026 · Updated 23 times
Summary
This early-phase trial tests two drugs (cosibelimab and balixafortide) in 24 people with metastatic pancreatic cancer that worsened after standard chemotherapy. The goal is to find the safest dose and see if the combination can help control the disease. Participants must be 18 or older and have measurable tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at SOCC
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.